Immunicum specialises in the research and development of novel immunotherapies that target hard-to-t...
Mangold tar upp bevakning av Miris med rekommendation Köp och en riktkurs på 3,00 kronor per aktie p...
Redeye provides its comments on RLS’ Q1’22 report. With reimbursement in place in the Netherlands as...
Imponerande Q1'22 ITAB rapporterade en EBIT på 92 mkr (102), 113 mkr (116) exklusive jämförelsestöra...
Redeye states that Catella’s Q1 report proved a new higher baseline for profitability in Investment ...
Redeye comments on Bredband2’s Q1’22, revealed earlier this morning.
Redeye comments on the Q1-report from Starbreeze. Net sales were SEK 23.
Ascelia can point to considerable professional interest and confirmed scientific support ahead of th...
Expanding pipeline to apathy in neurological disorders Pirepemat Ph 2b in PD-falls started in Q1 No ...
Redeye comments on Adverty’s Q1’22 report. Both sales and profitability came in below our estimates.
Raketech just released a soft Q1 report, and weak start to Q2.
Redeye updates its view on G5 following its Q1-results where the company’s hiked near-term UA invest...
Efterfrågan på Tessins tjänster är hög; intäkterna ökade med 37 procent under årets första kvartal j...
Strong Q1 beat driven by Principal Investments and PIM Underlying EPS estimates raised by 16% for 20...
Redeye is encouraged to see that Inzile has received an order of 21 Pro4’s from Tier Mobility.
Redeye return with a second comment following BIMobject's Q1-figures which were slightly above estim...
Finepart publicerade idag den 10 maj 2022 sin delårsrapport för första kvartalet 2022.
Q1 report due on Wednesday 25 May… …but the preliminary Q1 numbers are already out We expect sales o...
Redeye comments on Amniotics' first quarter and updates its Base Case.
New Wave Group fortsätter att imponera och växte omsättningen med 41 procent samt mer än fördubblade...
